Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the record history page.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe history now shows the study is no longer looking for participants, indicating enrollment has ceased. The entries also add a new revision label v3.6.0 as the current version, replacing the previous v3.5.5 reference.SummaryDifference0.2%

- Check23 days agoChange DetectedThe history shows Revision: v3.5.5, replacing the previous v3.5.4, indicating a new revision of the record was posted to update the entry.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page's revision label updates from v3.5.3 to v3.5.4. This represents a minor backend update affecting the record-history display.SummaryDifference0.1%

- Check66 days agoChange DetectedThe record history reflects a newer submitted version (including a “Study Status” update) and updates the displayed revision label to v3.5.3, replacing an older revision label entry. No concrete change to core study details is visible from the provided change text alone.SummaryDifference0.3%

- Check102 days agoChange DetectedThe history now shows a new revision entry v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.